WINNIPEG, MANITOBA--(Marketwired - Feb 4, 2014) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has received a total of $397,500 from the exercising of 2,650,000 warrants at $.15 per share from warrant holders. The warrants were issued on December 14, 2012 as part of a previously announced financing.
The warrants exercised included 1,400,000 warrants exercised by insiders of the company. The remaining warrants issued in conjunction with the financing have expired.
The Company is currently focusing its resources and capital in the companion animal market. The primary objective is to assess the company's StrixNB™ oral care products in regional markets to confirm communications, market strategy and tactics and to evaluate new formulations to enhance the product portfolio. StrixNB concentrate drinking water additive and oral care spray are currently approved by Health Canada's Low Risk Veterinary Heath Products program. In addition the company is developing a toothpaste and powder formulation.
Kane Biotech also continues to develop the DispersinB® dermatological product portfolio and has previously announced that it has received Health Canada's Low Risk Veterinary Health Products program approval for the company's first dermal care product DispersinB topical spray. Additional products in development include antibiofilm-antimicrobial (non-antibiotic) products for acute and chronic ear infections and shampoo for animal health care, and also a human skin care product for dermal infections such atopic dermatitis, eczema and psoriasis associated infections.
The Company also recently signed an agreement with a global healthcare company who has been assessing Kane Biotech's antibiofilm-antimicrobial technologies. The global healthcare company holds an option to obtain an exclusive, worldwide license to develop, commercialize and market certain oral and wound care technologies in the global animal health market.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 billion per year.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks of Kane Biotech Inc. All Rights Reserved 2014